Lundbeck gets marketing OK for Treanda in Canada

29 August 2012

Danish CNS drug specialist Lundbeck A/S (LUND: DC) says that medicines regulator Health Canada has approved Treanda (bendamustine hydrochloride for injection) to treat patients with relapsed indolent B-cell non-Hodgkin's lymphoma and chronic lymphocytic leukemia, following the success of the brand in both Europe and the USA.

Treanda, among a batch of other products, was licensed from Cephalon (now a wholly owned subsidiary of Teva Pharmaceutical Industries last year and Lundbeck was granted exclusive commercial rights in Canada (The Pharma Letter February 10, 2011). Under license from Japan’s Astellas Pharma, Cephalon and Teva holds exclusive rights to market and develop Treanda in the USA.

Expected to strengthen growth outlook

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK